Equasens Société anonyme (EQS) Trading Update summary

Full-year 2024 revenue performance

• Revenue for 2024 was €216.8m, down 1.4% reported and 3.7% like-for-like, reflecting a challenging market and the end of certain regulatory tailwinds.

• Q4 2024 revenue reached €58.6m, up 2.6% reported but down 0.4% like-for-like, showing signs of stabilization.

• Pharmagest division, the largest contributor (75.4% of revenue), grew 0.5% reported but declined 3.3% like-for-like; over 500 new pharmacy customers were added.

• Axigate Link division posted 3.2% reported and 5.5% like-for-like growth, driven by strong performance in nursing homes and homecare.

• E-Connect and Medical Solutions divisions saw declines, while Fintech remained stable; SaaS transition and new product launches are underway.

Business segment highlights

• Sale of configurations and hardware fell 7.9% for the year, but maintenance, training, and software subscriptions grew 3–4%.

• Pharmagest launched new AI-driven modules and payment terminals, boosting its value proposition and market share.

• Axigate Link expanded its SaaS offering, with Titanlink and PandaLab Pro seeing strong adoption and increased use cases.

• E-Connect launched new telecare and mobility solutions, with promising initial sales of KAP-eCV readers.

• Medical Solutions introduced LOQUii, an AI voice assistant, and MS.Safe backup, with early user traction.

Strategic initiatives and outlook

• SaaS transformation is accelerating, with new modules developed primarily for cloud deployment and recurring revenue.

• Investments in AI integration aim to enhance decision-making tools and secure prescription processes.

• External growth continues, with the acquisition of Calimed SAS in December 2024.

• 2025 guidance anticipates positive momentum in H1 and nearly 10% nominal growth in H2, driven by new solutions and capital expenditures.

• Financial structure remains solid, supporting ongoing innovation and M&A opportunities.